Cagrilintide 10 mg

This 10 mg vial of Cagrilintide is supplied as a higher-content format for multi-aliquot research applications. Cagrilintide 10mg peptide is a synthetic 37-residue long-acting amylin-analog research peptide engineered with a C16 fatty-acid acylation that extends the molecule's half-life for use in research models. By engaging amylin family receptors (calcitonin receptor and amylin receptor subtypes formed with receptor activity-modifying proteins, RAMPs), cagrilintide is investigated as an experimental research compound for studying amylin-pathway research, energy-metabolism research, and gastric-pathway research models in controlled laboratory settings.

Research interest in Cagrilintide 10mg peptide has focused on how long-acting amylin receptor engagement may modulate downstream metabolic-pathway research models. Mechanistic data indicate that cagrilintide interacts with both the calcitonin receptor and amylin receptor subtypes through structural modifications inherited from native amylin pharmacology, supporting laboratory research studies of receptor-binding research, gastric-pathway research, and energy-balance research models (Kruse et al., 2021, Journal of Medicinal Chemistry).

Beyond amylin-pathway research, Cagrilintide 10mg peptide has also been investigated in combined research models alongside GLP-1 receptor agonist peptides, where dual amylin and GLP-1 receptor engagement is studied as an integrated metabolic-pathway research model. These investigations have positioned cagrilintide as an experimental research compound of interest in studies of long-acting amylin receptor pharmacology and combined peptide receptor research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Cagrilintide is a synthetic 37-residue amylin-analog research peptide engineered for extended half-life through C16 fatty-acid acylation. The molecule was developed to overcome the short circulating half-life of native amylin and pramlintide research peptides, enabling once-weekly research dosing schedules in laboratory research studies.

Amylin is an endogenous 37-residue peptide co-secreted with insulin from pancreatic beta-cells in research models. Amylin receptor signaling research is associated with gastric-pathway research, neuroendocrine pathways relevant to energy-balance research, and glucose-signaling research. The development of cagrilintide as a long-acting amylin analog drew on structure-activity research to balance receptor selectivity, solubility, and pharmacokinetic stability (Kruse et al., 2021, Journal of Medicinal Chemistry).

This positioning at the intersection of amylin-pathway research and long-acting peptide engineering has made cagrilintide an experimental research compound of considerable interest in laboratory research studies of amylin receptor pharmacology, combined peptide research alongside GLP-1 receptor agonists, and integrated metabolic-pathway signaling research.

1. Amylin Receptor Engagement

Cagrilintide engages amylin family receptors, which are heterodimers of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Amylin receptor signaling research is associated with gastric-pathway research, central neuroendocrine modulation relevant to energy-balance research, and glucose-signaling research models.

2. Calcitonin Receptor Interaction

Cagrilintide also engages the calcitonin receptor directly, which is investigated in research models for its role in bone-remodeling research and broader neuroendocrine-pathway research. Structural research has characterized cagrilintide binding across calcitonin and amylin receptor subtypes (Kruse et al., 2021, Journal of Medicinal Chemistry).

3. C16 Fatty-Acid Acylation

The C16 fatty-acid side chain extends the half-life of cagrilintide in research models by promoting reversible albumin binding. This enables receptor-pharmacology research at extended timepoints and supports laboratory research studies that examine long-acting amylin receptor engagement.

4. Combined Peptide Research Models

Cagrilintide is frequently investigated in combined research models alongside GLP-1 receptor agonist peptides such as semaglutide. In these laboratory research studies, dual amylin and GLP-1 receptor engagement is studied as an integrated metabolic-pathway research model, distinct from selective single-receptor agonism.

Research Applications

Conclusion

Cagrilintide represents an experimental research compound class of long-acting amylin analogs engineered through fatty-acid acylation for extended half-life in research models. By engaging amylin and calcitonin receptor subtypes, cagrilintide supports laboratory research studies of amylin receptor pharmacology and combined peptide research models, making it a valuable research target for investigations of amylin-pathway research and integrated metabolic-pathway signaling research.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.